Phase I data show Theravance LAMA GSK1160724/TD-4208 safe in COPD patients « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Phase I data show Theravance LAMA GSK1160724/TD-4208 safe in COPD patients

Posted on July 15, 2008 by crimsoncanary

Theravance have announced Phase 1 data showing its long acting muscarinic antagonist (LAMA), GSK1160724/TD-4208 to be safe and well tolerated in the treatment of chronic obstructive pulmonary disease (COPD). Partner GSK have, however, informed Theravance that it intends to return the LAMA program to Theravance because the current formulation of TD-4208 is incompatible with GSK’s proprietary inhaler device.

Filed under: Uncategorized | Tagged: antagonist, GlaxoSmithkline, GSK, GSK-1160724, GSK1160724, LAMA, Licensing, Muscarinic, phase I, TD-4208, TD4208, Theravance

« Zealand Pharmaceutical’s GLP-1 Agonist AVE0010 enters Phase III trials in Patients With Type 2 Diabetes Univ Maryland publish series of Nociceptin/Orphanin FQ(1−13) Amide Analogues »

Leave a Reply